tetano
Editor, Senior Moderator
Ann Vasc Dis
. 2024 Mar 25;17(1):1-8.
doi: 10.3400/avd.oa.23-00031. Epub 2023 Nov 28. Prophylactic Anticoagulation and Thrombosis in Hospitalized Patients with Clinically Stable COVID-19 at Admission: From the Practice-Based Observational Study
Yugo Yamashita[SUP] 1 [/SUP], Sen Yachi[SUP] 2 [/SUP], Makoto Takeyama[SUP] 2 [/SUP], Yuji Nishimoto[SUP] 3 [/SUP], Ichizo Tsujino[SUP] 4 [/SUP], Junichi Nakamura[SUP] 4 [/SUP], Naoto Yamamoto[SUP] 5 [/SUP], Hiroko Nakata[SUP] 6 [/SUP], Satoshi Ikeda[SUP] 7 [/SUP], Michihisa Umetsu[SUP] 8 [/SUP], Shizu Aikawa[SUP] 9 [/SUP], Hiroya Hayashi[SUP] 10 [/SUP], Hirono Satokawa[SUP] 11 [/SUP], Yoshinori Okuno[SUP] 1 [/SUP], Eriko Iwata[SUP] 12 [/SUP], Yoshito Ogihara[SUP] 13 [/SUP], Nobutaka Ikeda[SUP] 14 [/SUP], Akane Kondo[SUP] 15 [/SUP], Takehisa Iwai[SUP] 16 [/SUP], Norikazu Yamada[SUP] 17 [/SUP], Tomohiro Ogawa[SUP] 18 [/SUP], Takao Kobayashi[SUP] 5 [/SUP], Makoto Mo[SUP] 19 [/SUP]; Clot-COVID Study Investigators
Affiliations
Objectives: The potential benefit of routine prophylactic anticoagulation for all hospitalized patients with clinically stable coronavirus disease 2019 (COVID-19) is still controversial. Method: The CLOT-COVID Study was a multicenter observational study enrolling 2894 consecutive hospitalized patients with COVID-19. The current study population consisted of 1738 hospitalized patients with mild COVID-19 at admission not requiring oxygen administration, who were divided into 2 groups: patients with prophylactic anticoagulation (n = 326) and those without (n = 1412). Results: Patients with prophylactic anticoagulation had more severe status of the worst severity of COVID-19 during hospitalization compared with those without (mild: 38% versus 82%, moderate: 55% versus 17%, and severe or death at discharge: 6.4% versus 0.7%, P <0.001). During hospitalization, 8 patients (0.5%) developed thrombosis, and the incidences of thrombosis were numerically higher in patients with more severe status of worst severity of COVID-19 during hospitalization (mild: 0.2%, moderate: 1.2%, and severe or death at discharge: 3.2%). Conclusions: Among hospitalized patients with clinically stable COVID-19 at admission, patients who did not worsen in COVID-19 severity after admission rarely developed thrombosis, although patients with worsening of COVID-19 severity after admission more often received prophylactic anticoagulation and might have a higher risk of thrombosis.
Keywords: COVID-19; anticoagulation; mild; stable; thrombosis.
. 2024 Mar 25;17(1):1-8.
doi: 10.3400/avd.oa.23-00031. Epub 2023 Nov 28. Prophylactic Anticoagulation and Thrombosis in Hospitalized Patients with Clinically Stable COVID-19 at Admission: From the Practice-Based Observational Study
Yugo Yamashita[SUP] 1 [/SUP], Sen Yachi[SUP] 2 [/SUP], Makoto Takeyama[SUP] 2 [/SUP], Yuji Nishimoto[SUP] 3 [/SUP], Ichizo Tsujino[SUP] 4 [/SUP], Junichi Nakamura[SUP] 4 [/SUP], Naoto Yamamoto[SUP] 5 [/SUP], Hiroko Nakata[SUP] 6 [/SUP], Satoshi Ikeda[SUP] 7 [/SUP], Michihisa Umetsu[SUP] 8 [/SUP], Shizu Aikawa[SUP] 9 [/SUP], Hiroya Hayashi[SUP] 10 [/SUP], Hirono Satokawa[SUP] 11 [/SUP], Yoshinori Okuno[SUP] 1 [/SUP], Eriko Iwata[SUP] 12 [/SUP], Yoshito Ogihara[SUP] 13 [/SUP], Nobutaka Ikeda[SUP] 14 [/SUP], Akane Kondo[SUP] 15 [/SUP], Takehisa Iwai[SUP] 16 [/SUP], Norikazu Yamada[SUP] 17 [/SUP], Tomohiro Ogawa[SUP] 18 [/SUP], Takao Kobayashi[SUP] 5 [/SUP], Makoto Mo[SUP] 19 [/SUP]; Clot-COVID Study Investigators
Affiliations
- PMID: 38628927
- PMCID: PMC11018098
- DOI: 10.3400/avd.oa.23-00031
Objectives: The potential benefit of routine prophylactic anticoagulation for all hospitalized patients with clinically stable coronavirus disease 2019 (COVID-19) is still controversial. Method: The CLOT-COVID Study was a multicenter observational study enrolling 2894 consecutive hospitalized patients with COVID-19. The current study population consisted of 1738 hospitalized patients with mild COVID-19 at admission not requiring oxygen administration, who were divided into 2 groups: patients with prophylactic anticoagulation (n = 326) and those without (n = 1412). Results: Patients with prophylactic anticoagulation had more severe status of the worst severity of COVID-19 during hospitalization compared with those without (mild: 38% versus 82%, moderate: 55% versus 17%, and severe or death at discharge: 6.4% versus 0.7%, P <0.001). During hospitalization, 8 patients (0.5%) developed thrombosis, and the incidences of thrombosis were numerically higher in patients with more severe status of worst severity of COVID-19 during hospitalization (mild: 0.2%, moderate: 1.2%, and severe or death at discharge: 3.2%). Conclusions: Among hospitalized patients with clinically stable COVID-19 at admission, patients who did not worsen in COVID-19 severity after admission rarely developed thrombosis, although patients with worsening of COVID-19 severity after admission more often received prophylactic anticoagulation and might have a higher risk of thrombosis.
Keywords: COVID-19; anticoagulation; mild; stable; thrombosis.